Technical Data
044874
GW1929 (N-(2-Benzoylphenyl)-L-tyrosine PPARgamma Agonist, (2S)-((2-Benzoylphenyl)amino-3-phenyl]propionic acid)
1mg
Biochemicals Storage: 4C/-20CShipping: Blue Ice
Potent and subtype-selective (>1000-fold) PPARgamma agonist. Angiogenesis inhibitor. Apoptosis inhibitor. Anti-inflammatory. Anti-hyperglycemic and anti-hyperlipidemic agent. Antidiabetic. The glucose-lowering effect in rats is 100-fold more potent than that of troglitazone.

Storage and Stability:
Short-term Storage: +4C
Long-term Storage: -20C
Stable for at least 2 years after receipt when stored at -20C. Store solutions at -20C in the dark.

CAS Number:
196808-24-9

Molecular Formula:
C30H29N3O4

Molecular Weight:
495.6
Purity: >98% (NMR)

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Product Reference:
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents: B.R. Henke, et al.; J. Med. Chem. 41, 5020 (1998)
A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat: K.K. Brown, et al.; Diabetes 48, 1415 (1999)
PPARgamma agonists inhibit angiogenesis by suppressing PKCalpha- and CREB-mediated COX-2 expression in the human endothelium: E. Scoditti, et al.; Cardiovasc. Res. 86, 302 (2010)
Ameliorative Effects of GW1929, a Nonthiazolidinedione PPAR gamma Agonist, on Inflammation and Apoptosis in Focal Cerebral Ischemic-Reperfusion Injury: R.K. Kaundal & S.S. Sharma; Curr. Neurovasc. Res. 8, 236 (2011)


Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.